Publications by authors named "M R Christiaens"
Article Synopsis
- - The phase 3 study ENGOT-cx11/GOG-3047/KEYNOTE-A18 found that adding pembrolizumab to standard chemoradiotherapy significantly improved progression-free survival in patients with advanced cervical cancer during the first interim analysis.
- - In this study, 1060 patients with high-risk cervical cancer were randomly assigned to receive either pembrolizumab or a placebo alongside chemoradiotherapy, with treatment outcomes evaluated at the second interim analysis.
- - The primary outcomes measured were progression-free survival and overall survival, focusing on patient mortality, with safety being a secondary consideration.
Background And Objective: In locally advanced cancer, bleeding is a common clinical presentation and radiotherapy (RT) provides a noninvasive, well-tolerated, cost-effective treatment. However, the choice for fractionation dose and schedule seem to merely depend on physician's preference rather than specific guidelines. We reviewed the available literature on palliative hemostatic RT for response rate (RR) and bleeding duration in relation with the given dose.
View Article and Find Full Text PDFArticle Synopsis
- Pembrolizumab, an immunotherapy drug, is being tested to see if it improves the effectiveness of chemoradiotherapy in patients with locally advanced cervical cancer, based on prior success in similar cases.
- This phase 3 trial involved multiple international centers and used a double-blind, placebo-controlled design to randomly assign participants to receive either pembrolizumab or a placebo alongside their treatment.
- The primary goals of the study were to measure progression-free survival and overall survival, assessing treatment safety in those who received at least one dose of the study medication.
Introduction: Lymphovascular space invasion (LVSI), deep (>1/3) stromal invasion (DSI) and large tumor size (>4 cm) have been identified as predictors for intermediate risk for recurrence according to Sedlis (at least two of the prior risk factors) in FIGO stage I cervical cancer. Adjuvant radiotherapy (RT) has been advocated in these patients(1,2), but remains controversial.
Method: All consecutive patients (1997-2017) with cervical cancer FIGO (2009) stage IB1 (≤4 cm) were included.